NCT05633602 2025-05-28Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudySWOG Cancer Research NetworkPhase 3 Active not recruiting838 enrolled